Therapeutic Goods Advertising Compliance: Understanding TGA Advertising Requirements

Therapeutic goods advertising compliance is an important consideration for Australian businesses advertising medicines, medical devices and other regulated therapeutic goods. The Therapeutic Goods Administration (TGA) regulates advertising of therapeutic goods under the Therapeutic Goods Act 1989 (cth) (the Act) and associated requirements, including the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021.
The consequences of non-compliance with the Act can be significant. Civil contraventions can attract maximum penalties of $1.82 million for an individual and $18.2 million for a body corporate. Serious criminal offences involving therapeutic goods can carry penalties of up to five years' imprisonment, a fine of up to $1.456 million, or both. The applicable penalty depends on the particular provision and circumstances of the conduct.
Understanding TGA advertising requirements involves more than checking individual marketing claims. Businesses need to consider whether content constitutes therapeutic goods advertising, whether the relevant product can be advertised to the intended audience, and whether the advertisement complies with applicable requirements.
These considerations can apply across websites, social media, digital advertising, health-service promotion, testimonials, influencers and other promotional communications. The regulatory question is therefore often broader than whether a particular advertisement contains an obviously problematic statement.
What Is Therapeutic Goods Advertising?
Therapeutic goods advertising can include material intended, directly or indirectly, to promote the use or supply of therapeutic goods. Whether particular content amounts to advertising needs to be considered in its overall context.
This means therapeutic goods advertising is not limited to traditional paid advertisements.
Websites, landing pages, social media posts, videos, blogs, digital campaigns and other communications may potentially be advertising depending on their purpose, content and presentation.
On social media, for example, the TGA identifies promotional activities including encouraging consumers to seek out a therapeutic good, encouraging its use, building product or brand loyalty, selling products or driving website traffic.
For businesses, this means the appropriate question is not simply, “Did we call this an advertisement? The more useful compliance question is “Does this communication, viewed in context, directly or indirectly promote the use or supply of a therapeutic good?”
Can Therapeutic Goods Be Advertised to the Public?
Some therapeutic goods can be advertised to the Australian public, while others are prohibited or restricted. Whether advertising is permitted depends on the therapeutic good and the regulatory requirements applying to it. This makes identifying whether content constitutes advertising only the first step. The organisation may also need to consider the type of product, its ingredients or scheduling, how it works, the intended audience and the representations being made.
The TGA explains that some therapeutic goods, including prescription medicines and biologicals, cannot generally be advertised to the public, while other products may be advertised provided the applicable legislative and Advertising Code requirements are satisfied.
Businesses should therefore establish whether the relevant therapeutic good can be advertised to the intended audience before considering how the advertisement should be worded.
TGA Advertising Requirements and the Therapeutic Goods Advertising Code
For therapeutic goods that can be advertised to the public, the Therapeutic Goods Advertising Code is a central part of the regulatory framework.
The current Code is the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021. It contains requirements applying to advertisements for therapeutic goods to the public.
Among the general requirements, the TGA states that advertisements must be accurate, balanced and not misleading, contain only substantiated claims and be consistent with the product's Australian Register of Therapeutic Goods entry where applicable.
Depending on the advertisement, additional requirements can concern mandatory information, testimonials and endorsements, restricted or prohibited representations, scientific or clinical representations and other matters.
Therapeutic goods advertising compliance therefore requires more than checking whether an isolated statement is technically correct.
The advertisement should be considered as a whole, including the claims made, images used, context, intended audience and overall impression created.
Prescription Medicine Advertising Restrictions
Prescription medicine advertising to the Australian public is subject to significant restrictions.
This is particularly important for businesses operating in areas involving prescription medicines, including medicinal cannabis, cosmetic medicine, telehealth, weight-management treatments and other health services where prescription medicines may form part of treatment.
The TGA's current guidance states that some therapeutic goods, including prescription medicines, cannot be advertised to the public. Its health-services guidance also addresses restrictions applying to Schedule 3, Schedule 4 and Schedule 8 substances and goods containing those substances, subject to relevant exceptions.
Importantly, compliance cannot necessarily be achieved simply by avoiding the formal product or brand name.
The TGA's current health-services guidance identifies circumstances where indirect references — including certain abbreviations, colloquial terms, descriptions and hashtags — can amount to references to prescription medicines.
Businesses operating in prescription-medicine environments should therefore consider their marketing as a whole, rather than assessing individual words in isolation.
Advertising Health Services Involving Therapeutic Goods
A particularly important distinction exists between advertising a health service and advertising therapeutic goods used in delivering that service.
The TGA does not regulate promotion of health services merely because they are health services. However, where advertising for a health service also advertises therapeutic goods, the requirements of the Therapeutic Goods Act can apply. The distinction can be subtle.
For example, marketing may begin as promotion of consultations or clinical services but potentially move into therapeutic goods advertising where it directly or indirectly promotes particular medicines or other therapeutic goods.
This can be particularly relevant to:
telehealth providers;
medicinal cannabis services;
cosmetic medicine;
weight-management services;
clinics;
online health platforms; and
other services involving regulated therapeutic goods.
Businesses should therefore consider the overall impression created by their advertising rather than relying solely on describing the offering as a “service”.
TGA Social Media Advertising Requirements
The same therapeutic goods advertising framework can apply to social media and other digital channels.
The TGA identifies social media posts, comments, hashtags, blogs, discussion forums and streaming services among the forms of content that can constitute therapeutic goods advertising.
That can include content appearing through platforms such as Facebook, Instagram, TikTok, LinkedIn and other social or digital channels. Businesses should also consider advertising undertaken on their behalf.
Influencers, content creators, marketing agencies and other third parties can create regulatory risk where promotional content concerns therapeutic goods. The TGA recommends businesses ensure influencers and content creators they engage understand that a product is a therapeutic good and are made aware of relevant advertising requirements.
For organisations using multiple digital marketing channels, therapeutic goods advertising compliance therefore requires appropriate governance over more than the organisation's own website.
Testimonials, Influencers and User-Generated Content
Testimonials, endorsements, reviews and user-generated content can create additional therapeutic goods advertising considerations.
This is particularly relevant on social media, where the boundary between content produced by the advertiser and material generated by other users can become less obvious.
Comments, product reviews, influencer content, links, tags and hashtags can affect the regulatory context of promotional material. The TGA's current social-media guidance also states that responsibility may extend to user-generated content, including third-party comments appearing on a business's social-media platforms.
Businesses should therefore consider:
what they publish;
what they commission others to publish;
what they repost or endorse;
influencer and content-creator arrangements;
comments and reviews appearing alongside promotional content;
links, tags and hashtags;
moderation arrangements; and
internal approval processes.
Advertising governance should not necessarily end when the original post is approved.
Building a Therapeutic Goods Advertising Compliance Framework
For organisations regularly advertising therapeutic goods, compliance is better treated as an organisational regulatory function than as a final marketing check immediately before publication.
A practical therapeutic goods advertising compliance framework might require the organisation to consider:
What product or service is being promoted?
Does the material potentially constitute therapeutic goods advertising?
Who is the intended audience?
Can the relevant therapeutic good be advertised to that audience?
What legislative and Advertising Code requirements apply?
Are representations and claims appropriately supported?
Is mandatory information required?
Are testimonials or endorsements involved?
Are influencers, agencies or other third parties involved?
Who has authority to approve publication?
What evidence of the compliance review is retained?
When should higher-risk advertising be escalated for specialist review?
This becomes particularly important where marketing activity is distributed across internal marketing teams, external agencies, contractors, influencers, related entities or multiple digital platforms.
A documented approval and escalation process can help an organisation identify potential compliance issues before publication, rather than only after a concern has been raised.
What to Do if the TGA Raises Advertising Compliance Concerns
Receiving correspondence or enquiries from the TGA concerning advertising or promotional conduct can require an organisation to quickly understand what occurred and the scope of the potential issue.
A structured response may involve several steps.
Establish What Conduct Occurred
Identify the relevant advertisements, webpages, communications, social-media material, products and promotional activity. The immediate issue raised by the regulator may not necessarily represent the full extent of the relevant conduct.
Establish the Relevant Period
Determine when the material was created, approved, published, modified and removed.
This can be particularly important for websites and social media where content may have changed over time.
Identify Who Was Involved
Establish who created, approved, instructed, published or controlled the relevant advertising. Relevant parties might include employees, executives, external marketing agencies, contractors, influencers or other businesses.
Preserve Relevant Evidence
Relevant evidence may include webpages, screenshots, advertisements, social-media content, correspondence, internal approvals, marketing instructions, contracts, campaign material and other records. Preserving the available evidence early can assist the organisation to establish what actually occurred.
Consider Whether the Issue Is Isolated or Systemic
An organisation should consider whether the regulatory concern relates to one advertisement or indicates a broader issue.
Similar wording, campaigns, templates or approval practices may exist elsewhere across the organisation.
Consider Immediate Remediation
Potentially problematic content may require prompt review.
Depending on the circumstances, remediation may extend beyond individual advertising and involve approval processes, policies, governance, staff guidance or other controls.
Review the Underlying Compliance System
Once the immediate issue is understood, the organisation can consider why it occurred.
Was there an adequate advertising approval process
Were responsibilities clear?
Was appropriate regulatory expertise involved?
Were claims substantiated?
Were third-party marketers appropriately instructed?
Was higher-risk content escalated?
A regulatory response can therefore provide an opportunity to address both the immediate concern and the underlying compliance system.
Where correspondence raises questions of legal liability, statutory interpretation or potential formal enforcement action, organisations should consider obtaining appropriate independent legal advice or the assistance of regulatory consultant such as IntegriRisk.
Responding to a TGA Advertising Compliance Concern?
If your organisation has identified a potential therapeutic goods advertising issue or received correspondence concerning its advertising or promotional conduct, early assessment can help establish the scope of the issue, preserve relevant evidence and identify appropriate remediation.
IntegriRisk provides specialist Therapeutic Goods & TGA Compliance Advisory support, including advertising compliance reviews, regulatory response support, evidence and conduct assessment, remediation and compliance-system improvement.
Where legal advice or representation is required, IntegriRisk can provide regulatory, factual and operational support alongside an organisation's legal advisers.
Discuss your regulatory matter confidentially with IntegriRisk.
Useful Links and References:
This article provides general information only and does not constitute legal advice. Regulatory requirements depend on the circumstances of each matter. Organisations should obtain appropriate professional or legal advice where required.

Comments